eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2020
vol. 45
 
Share:
Send email
Share:
abstract:
Case report

Late Epstein-Barr virus-related post-transplant lymphoproliferative disorder with intestinal involvement in patient with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Hedda Kloster Hjellbakk
1
,
Monika Małgorzata Adamska
1, 2
,
Bartosz Małecki
2
,
Katarzyna Brzeźniakiewicz-Janus
3
,
Anna Łojko-Dankowska
2
,
Lidia Gil
2

  1. Hematology Research Group, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland
  3. Department of Hematology, University of Zielona Gora, Multi-Specialist Hospital, Gorzow Wielkopolski, Poland
Cent Eur J Immunol 2020; 45 (2): 233-236
DOI: https://doi.org/10.5114/ceji.2020.96930
Online publish date: 2020/07/09
View full text Get citation
 
PlumX metrics:
Post-transplant lymphoproliferative disorder (PTLD) is a rare, but severe Epstein-Barr virus (EPV)-driven disorder that manifest after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). This heterogenous disease may manifest as localized or disseminated, and clinical presentation may differ significantly. It may be difficult to early diagnose PTLD, as is may be misdiagnosed as infection or graft rejection. The majority of EBV-PTLD typically occurs within four months following HSCT, and almost all cases present within the first year. EBV-PTLD that manifests > 5 years is considered an exceedingly rare occurrence.

We describe a case of 66-year-old male, who was diagnosed with high-risk chronic lymphocytic leukemia (CLL). He underwent allogeneic HSCT from HLA-identical sister, and subsequently developed acute followed by chronic graft-versus-host disease, for which he was long-term treated with immunosuppressants. At 6 years following HSCT, the patient presented with life-threatening perforation of gut. Histological evaluation revealed diffuse large B cell lymphoma. Serum sample test showed positive EBV DNA and diagnosis of probable EBV-PTLD was done. After the treatment with rituximab, along with the reduction of immunosuppression, the patient achieved complete remission. Late onset EBV-PTLD after HSCT is extremely uncommon, and hardly described in literature.
keywords:

hematopoietic stem cell transplantation, post-transplant lymphoproliferative disorder, late onset
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.